Health Care Professional survey on understanding of key risk minimisation measures related to interstitial lung disease (ILD) / pneumonitis with Trastuzumab Deruxtecan treatment First published 24/03/2022 Last updated 27/05/2024 EU PAS number:EUPAS46367 Study Finalised